Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04055688|
Recruitment Status : Recruiting
First Posted : August 14, 2019
Last Update Posted : September 5, 2019
5-ALA and the Orbeye surgical microscope are U.S. Food and Drug Administration (FDA) approved products. For this study, the Orbeye microscope imaging system is being used with special filters to visualize 5-ALA fluorescence. The FDA currently permits the use of these filters. The purpose of this study is to collect medical information before, during, and after standard treatment in order to better understand how to make this type of procedure accessible to patients.
This study is also being conducted to determine if use of the Orbeye equipped with these special filters improves the ability of the surgeon to remove brain tumors.
|Condition or disease||Intervention/treatment|
|Brain Tumor Glioma||Device: Orbeye surgical videomicroscope Drug: 5-Aminolevulinic Acid|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Clinical Study of the Utility of a Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas|
|Actual Study Start Date :||August 8, 2019|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
|Participants with known or suspected high grade gliomas||
Device: Orbeye surgical videomicroscope
The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
Drug: 5-Aminolevulinic Acid
5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
Other Name: 5-ALA
- Compare Visualized Fluroescence within brain tumors [ Time Frame: Surgery day one ]6 tissue samples will be obtained intraoperatively for each patient and assessed for 5-ALA visualization (strongly positive.weakly positive/negative). Tissue samples will be submitted for pathological assessment to determine whether tumor cells are present or absent. Visualization results will be evaluated against the pathology results (gold standard) to determine the sensitivity, specificity, positive predictive value and negative predictive value for 5-ALA visualizations with use of the ORBEYE system.
- Volume of Residual tumor [ Time Frame: up to 48 hours after surgery ]Residual tumor volume will be identified in post surgical MRI scans. Extent of resection will be compared to preoperative MRI scans.
- Number of Patients experiencing Adverse Events [ Time Frame: Up to 16 days after surgery ]Patients will be assessed for neurological and general side effects/toxicities 7-16 days after surgery.
- Post Surgery Questionnaire [ Time Frame: Surgery day one ]Surgeons will complete a questionnaire after each surgery to assess the visual experience of using the ORBEYE during the surgical procedure. The questionnaire asks about the superiority of the ORBEYE system compared to conventional binocular microscope, using a scale of 1-5, 1 being strongly agree and 5 being strongly disagree.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04055688
|United States, Florida|
|H. Lee Moffitt Cancer and Research Institute||Recruiting|
|Tampa, Florida, United States, 33612|
|Contact: Yazmin Rodriguez 813-745-3353 Yazmin.Rodriquez@Moffitt.org|
|Principal Investigator: Michael A Vogelbaum, MD, PhD|
|Sub-Investigator: James Liu, MD|
|Sub-Investigator: Arnold Etame, MD, PhD|
|Sub-Investigator: Nam Tran, MD, PhD|
|Sub-Investigator: Richard Macaulay, MD|
|Principal Investigator:||Michael A Vogelbaum, MD, PhD||H. Lee Moffitt Cancer and Research Institute|